Form 4: Blueprint Medicines CEO Kate Haviland Reports Stock and Option Transactions

CEO Kate Haviland reports acquisition of restricted stock units and stock options in Blueprint Medicines Corp.

Summary

• On March 1, 2025, Kate Haviland, CEO of Blueprint Medicines Corp, acquired 35,200 restricted stock units and 70,400 stock options.
• The restricted stock units were granted under the Issuer's 2024 Stock Incentive Plan.
• The stock options have an exercise price of $96.57 and expire on February 28, 2035.
• The options vest monthly starting April 1, 2025, over a period of 48 months.
• Following these transactions, Haviland directly owns 184,578 shares of common stock and 70,400 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The grant of restricted stock units and stock options to the CEO aligns her interests with those of the shareholders.
• The vesting schedule of the options encourages long-term commitment from the CEO.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management incentives with shareholder value.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include a mix of salary, stock options, and restricted stock units.
• Companies like Amgen, Gilead, and Regeneron also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and exercise prices are typically structured to align with long-term company performance.

Stakeholder Impact

• The equity grants incentivize the CEO to increase shareholder value.
• Employees may be indirectly impacted by the CEO's increased motivation to improve company performance.

Key Dates